David J. Chang leads all clinical programs at Cabaletta Bio, which seeks to develop and launch the first, potentially curative, targeted cellular therapies for patients with autoimmune diseases. He is directing development of Cabaletta’s pipeline, including CABA-201, a fully human, 4-1BB containing CD19-CAR T cell product candidate, which has potential application across a broad range of autoimmune diseases such as SLE, rheumatoid arthritis, myositis, and systemic sclerosis. He is also leading programs with the highly specific Chimeric AutoAntibody Receptor T (CAART) approach, a precision therapy to eliminate disease-causing B cells, which is currently being evaluated in multiple clinical trials. Dr. Chang is a rheumatologist who received his medical education and training at NYU and Cornell and has >25 years of experience in immune-inflammation clinical development including as SVP of Inflammation, Autoimmunity and Neuroscience at AstraZeneca and in various senior positions at GSK. He also holds an adjunct professorship at the University of Pennsylvania.
Track Chair: Sharon Benzeno, Adaptive Biotechnologies